New FDA Approval: Lenvatinib

Editors Note: This is a test post. We're doing this to gather feedback from you. Do you like this format for new FDA approval posts? Do you dislike it? Please let us know in the comments!

If feedback is positive, we will post something similar to this when new drugs are approved by the FDA.

Drug:

Lenvatinib [Lenvima]

Indication:

Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer

I’m sorry, what in the heck did you just say?

Lenvatinib can be used to treat the vast majority of thyroid cancers (differentiated thyroid cancers account for about 94% of all thyroid carcinomas according to NCCN)--after they have failed radiation therapy.

FDA Approval, ClinicalBrandon DysonMarch 2, 2016lenvatinib, thyroid, thyroid cancer, thyroid disease, sorafenib